
Triamcinolone is effective in chemotherapy-naïve CRPC. This phase II study (55 patients) found a median radiological PFS of 9.4 months, with a 6-month PFS rate of 69.1%. The 50% PSA response rate was 63.6%. Common toxicities included hypertension (44%) and proximal myopathy (40%), but no weight gain was observed. Triamcinolone offers a unique side-effect profile and benefits from supervised administration in CRPC treatment.
Like
Save
Share